OpGen (OPGN) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of OpGen (NASDAQ:OPGN) from a buy rating to a hold rating in a report published on Wednesday morning.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

A number of other brokerages have also recently commented on OPGN. ValuEngine upgraded shares of OpGen from a hold rating to a buy rating in a research note on Tuesday, July 10th. HC Wainwright set a $8.00 price target on shares of OpGen and gave the stock a buy rating in a research note on Friday, August 3rd.

OPGN traded up $0.02 during midday trading on Wednesday, reaching $1.34. 300 shares of the company’s stock were exchanged, compared to its average volume of 177,892. The stock has a market cap of $8.45 million, a price-to-earnings ratio of -0.14 and a beta of 1.94. The company has a quick ratio of 1.99, a current ratio of 2.13 and a debt-to-equity ratio of 0.19. OpGen has a one year low of $1.18 and a one year high of $7.75.

A hedge fund recently bought a new stake in OpGen stock. Acadian Asset Management LLC acquired a new position in shares of OpGen Inc (NASDAQ:OPGN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 58,906 shares of the medical research company’s stock, valued at approximately $105,000. Acadian Asset Management LLC owned approximately 0.99% of OpGen at the end of the most recent quarter. Institutional investors and hedge funds own 11.36% of the company’s stock.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Featured Story: Balance Sheet

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply